Phase II Trial of Erlotinib in Advanced Pancreatic Cancer

NCT00497224 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Cancer
Pancreas

Interventions

DRUG: Erlotinib

Sponsor

University Health Network, Toronto

Collaborators

[object Object]